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Secretory phospholipases A2 (sPLA2) are enzymes released during inflammatory
reactions. These molecules activate immune cells by mechanisms either related or
unrelated to their enzymatic activity. We examined the signaling events activated by
group IA (GIA) and group IB (GIB) sPLA2 in human lung macrophages leading to
cytokine/chemokine production. sPLA2 induced the production of cytokines (TNF-a,
IL-6 and IL-10) and chemokines (CCL2, CCL3, CCL4 and CXCL8), whereas no effect was
observed on IL-12, CCL1, CCL5 and CCL22. sPLA2 induced the phosphorylation of the
MAPK p38 and ERK1/2, and inhibition of these kinases by SB203580 and PD98059,
respectively, reduced TNF-a and CXCL8 release. Suppression of sPLA2 enzymatic
activity by a site-directed inhibitor influenced neither cytokine/chemokine production
nor activation of MAPK, whereas alteration of sPLA2 secondary structure suppressed
both responses. GIA activated the phosphatidylinositol 3-kinase (PI3 K)/Akt system and
a specific inhibitor of PI3 K (LY294002) reduced sPLA2-induced release of TNF-a and
CXCL8. GIA promoted phosphorylation and degradation of IjB and inhibition of NF-jB
by MG-132 and 6-amino-4-phenoxyphenylethylamino-quinazoline suppressed the
production of TNF-a and CXCL8. These results indicate that sPLA2 induce the
production of cytokines and chemokines in human macrophages by a non-enzymatic
mechanism involving the PI3 K/Akt system, the MAPK p38 and ERK1/2 and NF-jB.
Supporting information for this article is available at
http://www.wiley-vch.de/contents/jc_2040/2006/35567_s.pdf
Introduction
Secretory phospholipases A2 (sPLA2) are emerging as a
novel class of inflammatory mediators [1]. These
molecules are released in large quantities in the blood
and biological fluids of patients with inflammatory,
allergic and autoimmune disorders. Furthermore, sev-
eral sPLA2 possess potent proinflammatory activities
both in vitro and in vivo [2].
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Secretory PLA2 catalyze the hydrolysis of membrane
phospholipids to produce free arachidonic acid and
lysophospholipids. Indeed, several studies have shown
that these enzymes contribute to the biosynthesis of
lipid mediators in inflammatory cells [3]. However,
sPLA2 exert other biological effects relevant to the
initiation and regulation of inflammatory and immune
responses. These include the induction of exocytosis [4,
5], the production of cytokines [4, 6, 7], chemokines [7,
8] and NO [9, 10], the expression of surface molecules
[7, 11, 12], the recruitment of inflammatory cells [13,
14] and the enhancement of cell survival [15, 16]. Most
of these effects are unrelated to sPLA2 enzymatic activity
and involve the interaction of sPLA2 with such
membrane targets as heparin-containing proteoglycans
or specific receptors such as the M-type [17].
We have previously shown that both human and
venom sPLA2 are potent stimuli for cytokine production
in human lung macrophages (HLM) [4, 18], blood
monocytes [6] and eosinophils [7]. Other groups have
shown that sPLA2 induce the release of CXCL8/IL-8 [19]
from human neutrophils and of various CXC chemokines
from endothelial cells [8]. The production of cytokines
and chemokines in human inflammatory cells requires
activation of gene transcription and protein synthesis
[20]. These events are initiated and regulated by a
number of intracellular kinases, which in turn drive
membrane signals to nuclear factors, themost important
of which is NF-jB [21]. Among signaling kinases, the
phoshatidylinositol 3-kinase (PI3 K) and the MAPK p38
and extracellular-regulated kinases (ERK) 1/2 play a
prominent role in the regulation of immune cell
functions [22–24]. For example, they are involved in
the pathways leading to cytokine production in human
and murine macrophages stimulated with LPS or PMA
[25, 26]. However, the involvement of these kinases in
the intracellular signaling activated by sPLA2 in human
macrophages and their role in sPLA2-induced produc-
tion of cytokines and chemokines has not been defined
yet. In this study we have examined several signaling
events involved in the production of cytokines and
chemokines in primary HLM activated by two distinct
sPLA2.
Results
Activation of cytokine and chemokine production
in HLM by sPLA2
In the first group of experiments, we examined the
profile of cytokines and chemokines produced by HLM
stimulated with sPLA2. In this study we used group IA
(GIA) sPLA2 which is the most potent sPLA2 activating
HLM and human monocytes [4, 6]. Fig. 1A shows that
GIA induced a concentration-dependent release of
TNF-a, IL-6 and IL-10 from HLM. In these experiments,
GIA did not induce IL-12 release, even when the cells
were preincubated (37C,1 h) with IFN-c (1000 U/mL).
Under the same conditions, HLM stimulated with LPS
(1 lg/mL) released significant amounts of IL-12 (LPS:
122  16 pg/mg protein; unstimulated cells:
22  3 pg/mg protein; p<0.01). Incubation of HLM
with GIA also resulted in the release of the chemokines
CCL2/monocyte chemoattractant protein-1 (MCP-1),
CCL4/macrophage inflammatory protein-1b (MIP-1b)
and CXCL8/IL-8 (Fig. 1B). No effect of GIAwas observed
on CCL22/macrophage-derived chemokine (MDC) re-
lease. Interestingly, HLM produced this chemokine
when stimulated with 50 ng/mL IL-4 (IL-4:
7.73  1.79 ng/mg protein; unstimulated cells
2.22  0.54 ng/mg protein; p<0.01) [27]. These ex-
periments indicated that GIA elicit the production of
several cytokines (TNF-a > IL-6 > IL-10) and chemo-
kines (CXCL8 >> CCL4 > CCL2) in HLM. Kinetics
Figure 1. Effect of GIA sPLA2 on cytokine and chemokine
release from HLM. The cells were incubated (37C, 6 or 24 h)
with the indicated concentrations of GIA. (A) Cytokine (TNF-a,
IL-6, IL-10 and IL-12) and (B) chemokine (CCL2/MCP-1, CCL4/
MIP-1b, CCL22/MDC and CXCL8/IL-8) release was determined
in the supernatants by ELISA. The data are themean SE of six
experiments. *p<0.05 vs. control
Eur. J. Immunol. 2006. 36: 1938–1950 Leukocyte signaling 1939
f 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
experiments revealed that the optimal secretion of
cytokines and chemokines was reached at different time
points after the addition of GIA. TNF-a, IL-6, CCL4 and
CXCL8 release was maximum between 4 and 6 h of
incubation, whereas the release of IL-10 and CCL2
peaked between 18 and 24 h (data not shown).
It has been previously shown that the release of
cytokines induced by sPLA2 is associated with the
activation of their gene transcription [4, 6, 7]. To verify
that this also occurred for sPLA2-induced chemokine
secretion, we examined chemokine mRNA expression by
RNase protection assay (RPA). Fig. 2 shows a repre-
sentative experiment out of three in which HLM were
cultured for 6 h with medium alone (Ctr) or with the
indicated concentrations of GIA or LPS. HLM constitu-
tively express mRNA for CCL1/I-309, CCL3/MIP-1a,
CCL4 and CXCL8. As expected on the basis of the results
presented in Fig. 1B, GIA induced a concentration-
dependent increase of the expression of CCL2, CCL4 and
CXCL8 mRNA. In addition, CCL3 mRNA was also
increased, whereas GIA had no effect on the expression
of CCL1 and CCL5/RANTES. LPS, used as positive
control, up-regulated the mRNA for all the chemokines
examined. Data obtained from three different experi-
ments indicated that the GIA, at the maximal concen-
tration used (10 lg/mL), induced an enhancement of
mRNA expression ranging from 1.9- to 3.7-fold for
CCL2, from 4.3- to 6.2-fold for CCL3, from 3.1- to
5.5-fold for CCL4, and from 2.5- to 4.2-fold for CXCL8.
Role of p38 and ERK1/2 in sPLA2-induced
production of cytokines and chemokines in HLM
Activation of p38 and ERK1/2 is crucial for IL-6 and
TNF-a production induced by LPS in alveolar macro-
phages [25]. To clarify the intracellular mechanisms by
which sPLA2 promote cytokine and chemokine produc-
tion in macrophages, we initially examined whether GIA
activates p38 and ERK1/2. HLM were stimulated with
GIA (5 lg/mL) for various times and the phosphoryla-
tion of p38 and ERK1/2 was evaluated using anti-
phospho-specific Ab. Fig. 3A shows that GIA induced a
time-dependent phosphorylation of both p38 (first gel)
and ERK1/2 (third gel). Densitometric analysis of the
signal intensity obtained in four different experiments
revealed that the effect of GIA on both kinases was
evident after 5 min of incubation, peaked at 90 min and
persisted up to 120 min (Fig. 3B).
To verify that activation of MAPK was required for
cytokine and chemokine production, we evaluated the
effect of specific inhibitors of p38 (SB203580) [28, 29]
and of ERK1/2 (PD98059) [29, 30] on the release of the
major cytokine (TNF-a) and chemokine (CXCL8)
produced by sPLA2-stimulated HLM. Preliminary ex-
periments showed that complete inhibition of p38
activation occurred with 30 lM SB203580, whereas
ERK1/2 phosphorylation was completely blocked with
50 lM PD98059 (data not shown). The cells were
preincubated (37C,1 h) with increasing concentrations
of SB203580 (3–30 lM), PD98059 (10–50 lM) or with
a combination of the two inhibitors (30 lMSB203580+
50 lM PD98059) before stimulation with GIA. Both
SB203580 and PD98059 inhibited GIA-induced release
of TNF-a (Fig. 3C) and CXCL8 (Fig. 3D) in a
concentration-dependent fashion. The inhibitory effect
of the two compounds alone was slightly more evident
on TNF-a release (30 lM SB203580, 13.4% of the
maximal response; 50 lM PD98059, 21.5%) than it was
on CXCL8 release (30 lM SB203580, 27.5%; 50 lM
PD98059, 41.6%). Incubation of HLM with both
inhibitors completely blocked the secretion of TNF-a
and CXCL8 induced by GIA.
These results demonstrate that GIA activates p38 and
ERK1/2 in HLM and that both kinases are involved in the
production of TNF-a and CXCL8. Importantly, our data
indicate that simultaneous inhibition of these kinases is
required to fully suppress cytokine and chemokine
production in human macrophages.
Figure 2. Effect of GIA sPLA2 on chemokine mRNA expression
in HLM. The cells were incubated (37C, 6 h) with the indicated
concentrations of GIA or LPS. Total RNA was extracted and
expression of the various chemokinemRNA (CCL1/I-309, CCL2/
MCP-1, CCL3/MIP-1a, CCL4/MIP-1b, CCL5/RANTES, CXCL8/IL-8,
CXCL10/IP-10) was evaluated by RPA as described in the
Materials and methods. The expression enhancement of the
various mRNA is indicated by the number reported on each
sample representing the fold increase over untreated cells
(Ctr). The experiment shown is representative of three.
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Role of enzymatic activity in sPLA2-induced
activation of p38 and ERK1/2 in HLM
Some of the biological responses induced by sPLA2 are
mediated by their enzymatic activity [3]. GIA mobilizes
fatty acids from membrane phospholipids when added
exogenously to intact mammalian cells [6, 31]. There-
fore, we evaluated whether the effects of this sPLA2 on
HLM were related to its enzymatic activity using GIA
inactivated by treatment with bromophenacyl bromide
(BPB) or dithiothreitol (DTT). Both procedures irrever-
sibly inhibit more than 98% of GIA enzymatic activity [6,
7]. BPB blocks sPLA2 hydrolytic activity by binding to
the catalytic site [32], whereas DTTalters the secondary
structure of the molecule by breaking disulfide bridges
[33]. Control experiments indicated that BPB- and
DTT-inactivated GIA used in these experiments had
1.9% and 1.6% of the enzymatic activity remaining,
respectively. HLM stimulated with BPB-inactivated GIA
released TNF-a and CXCL8 in amounts comparable to
those induced by the active GIA (Supplementary
Table 1). In contrast, treatment with DTT completely
abolished the capacity of GIA to induce the release of
TNF-a and CXCL8. Similarly, when compared to the
active sPLA2, BPB-treated GIAwas still able to induce the
phosphorylation of p38 (Fig. 4A, first gel) and of
ERK1/2 (Fig. 4A, third gel) whereas DTT-treated GIA
lost its ability to activate both MAPK (Fig. 4B). In these
experiments, incubation of HLM with BPB, DTT or
DMSO (vehicle) in the absence of GIA did not influence
the basal release of TNF-a and CXCL8 nor affectedMAPK
activation. In addition, under conditions in which DTT
completely suppressed PLA2-induced release, it did not
affect the release of TNF-a and CXCL8 induced by LPS
(Supplementary Table 1), revealing that DTT does not
aspecifically influence the capacity of HLM to produce
cytokines and chemokines.
Figure 3. Role of p38 and ERK1/2 in GIA sPLA2-induced activation of TNF-a and CXCL8 release in HLM. (A, B) Kinetics of p38 and
ERK1/2 phosphorylation induced by GIA in HLM. The cells were stimulated with GIA (5 lg/mL) for the times indicated. Cellular
protein extracts were subjected to Western blot analysis with anti-phospho-p38 (first gel) and -phospho-ERK1/2 (third gel) Ab.
Stripped membranes were reblotted with anti-p38 (second gel) and -ERK2 (fourth gel) to confirm equal protein content of each
sample. The Western blots shown are representative of four separate experiments. (B) Densitometric analysis of the
phosphorylation kinetics of p38 and ERK1/2 was performed by measuring the signal intensity at the various time points and by
calculating the ratio versus untreated samples (Ctr). Adequate normalization was accomplished bymeasuring the signal intensity
of unphosphorylated forms of p38 and ERK2. The data shown in (B) are themean SE of the four experiments. (C, D) Effect of p38
and ERK1/2 inhibitors on sPLA2-induced TNF-a and CXCL8 release: The cells were preincubated (37
C, 1 h) with SB203580
(3–30 lM), PD98059 (10–50 lM) or both (30 lM SB203580 + 50 lM PD988059) and then stimulated (37C, 6 h) with GIA (10 lg/mL).
TNF-a and CXCL8 release was determined in the supernatants by ELISA. The data are the mean  SE of four experiments. *p<0.05
vs. GIA; § p<0.01 vs. GIA.
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These results indicate that selective blockade of
sPLA2 enzymatic activity by an active site-directed
inhibitor does not prevent sPLA2-induced effects,
whereas alteration of sPLA2 secondary structure by a
reducing agent (DTT) abolishes its ability to activate
HLM.
Activation of cytokine/chemokine production and
p38 and ERK1/2 phosphorylation in HLM by
human group IB sPLA2
To verify a human sPLA2 was able to activate cytokine/
chemokine production and to induce phosphorylation of
p38 and ERK1/2, HLM were stimulated with recombi-
nant human group IB sPLA2 (GIB). It has previously
shown that GIB activates HLM independently from its
enzymatic activity [18], and it is a ligand of the M-type
receptor in a murine system [34]. Fig. 5A shows that GIB
induced a concentration-dependent release of TNF-a
and CXCL8. Maximal release induced by GIB was
comparable to that induced by GIA. In addition, GIB
induced phosphorylation of both p38 (Fig. 5B, first gel)
and ERK1/2 (Fig. 5B, third gel). As for GIA, SB203580
and PD98059, when used alone, reduced the release of
TNF-a and CXCL8 induced by GIB, whereas the
combination of the two inhibitors completely blocked
this effect. Me-indoxam is the only molecule so far
reported to block the interaction of sPLA2 with its
specific M-type receptor [34]. Fig. 5B shows that
Me-indoxam prevented phosphorylation of both p38
and ERK1/2 induced by GIB.
These results indicate that a sPLA2 of human origin is
able to activate TNF-a and CXCL8 release as well as p38
and ERK1/2 phosphorylation, and confirm that both
MAPK are involved in sPLA2-induced production of
cytokines and chemokines in HLM. Activation of MAPK
induced by GIB is inhibited by preventing the interaction
of the sPLA2 with its putative membrane target M-type
receptor.
Role of PI3K in sPLA2-induced production of
cytokines and chemokines in HLM
It has been reported that activation of PI3 K is required
for TNF-a and IL-6 production in RAW 264.7 macro-
phages stimulated with LPS or PMA [26]. To investigate
whether PI3 K had a role in sPLA2-induced activation of
human macrophages, we initially studied the effect of
GIA on the phosphorylation of the regulatory subunit
(p85a) of PI3 K [35]. Protein extracts from HLM
stimulated with GIA (5 lg/mL) were analyzed by
immunoprecipitation with the anti-p85a Ab and sub-
sequent immunoblot with anti-phosphotyrosine Ab
(4G10). In these experiments a short incubation time
(1–15 min) was used since phosphorylation of p85a has
been characterized as an early event in the intracellular
signaling cascade [24, 36, 37]. Stimulation of HLM with
GIA resulted in the phosphorylation of p85a detectable
at 1 and 5 min, which was no longer evident at 15 min
(Fig. 6A, upper gel). However, even though a consider-
able amount of p85a was immunoprecipitated (Fig. 6A,
lower gel), the phosphorylation signals in these
experiments were relatively weak. Therefore, we con-
firmed that sPLA2 effectively induced activation of PI3 K
by exploring the phosphorylation kinetics of Akt. This
Ser/Thr kinase is a major downstream target of PI3 K
whose activation is necessary and sufficient for the
phosphorylation of Akt at the residues Thr308 and
Ser473 [38]. Fig. 6B shows the results of a typical
Figure 4. Effect of BPB- and DTT-inactivated GIA sPLA2 on
MAPK activation in HLM. The cells were incubated (37C, 1 h)
with the indicated concentrations of DMSO (vehicle)-, BPB- (A)
and DTT-treated (B) GIA. Western blot analysis with anti-
phospho-p38 (first gels) and -phospho-ERK1/2 (third gel) Ab
was performed. Stripped membranes were reblotted with
anti-p38 (second gels) and -ERK2 (fourth gels) to confirm equal
protein content of each sample. The Western blots shown are
representative of three separate experiments.
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experiment in which GIA induced a rapid phosphoryla-
tion of Akt as detected by two different Ab directed
against Akt when it is phosphorylated at Thr308 (first
gel) and at Ser473 (second gel). Densitometric analysis
performed on three different experiments confirmed
that phosphorylation of Akt occurred early, peaking at
5 min and declining to the basal level within 60 min
(Fig. 6C). Together these data indicate that GIA induces
the early activation of the PI3 K/Akt pathway.
To explore the functional involvement of PI3 K in the
production of TNF-a and CXCL8, HLM were preincu-
bated (37C, 1 h) with increasing concentrations
(3–30 lM) of a specific PI3 K inhibitor (LY294002)
[29, 39], and then stimulated with GIA (10 lg/mL).
Fig. 7A shows that LY294002 concentration-depen-
dently inhibited GIA-induced release of both TNF-a and
CXCL8. However, LY294002 (30 lM) almost completely
abolished the release of TNF-a (15.8% of the maximal
response), whereas it only partially inhibited the release
of CXCL8 (49.2% of the maximal response). These
results are somehow reminiscent of those obtained with
the inhibitors of p38 and ERK1/2 when used alone,
suggesting that PI3 K could be involved in the activation
of one of these MAPK. To verify this hypothesis, we
analyzed the effect of LY294002 (30 lM) on GIA-
induced activation of p38 and ERK1/2. The inhibitor
blocked the phosphorylation of ERK1/2 (Fig. 7B, third
gel), but it had no effect on GIA-induced phosphoryla-
tion of p38 (Fig. 7B, first gel). These results indicated
that PI3 K is involved in sPLA2-induced production of
TNF-a and CXCL8 as well as in the activation of ERK1/2.
Role of NF-jB in sPLA2-induced production of
cytokines and chemokines in HLM
NF-jB is a major nuclear factor regulating the
transcription of several genes encoding for inflamma-
tory cytokines and chemokines [21]. This dimeric
protein is complexed in the cytosol of resting cells with
specific inhibitors belonging to the IjB family. Cell
activation leads to the phosphorylation of IjB and its
subsequent degradation via the ubiquitin-proteasome
pathway [40]. This event allows the translocation of
NF-jB to the nucleus, where it binds to specific DNA
sequences. We tested the hypothesis that sPLA2 activate
NF-jB by exploring the kinetics of phosphorylation and
degradation of IjB in HLM. Fig. 8A shows that GIA
induced both the phosphorylation (upper gel) and the
degradation (lower gel) of IjB. As expected, the
phosphorylation of IjB preceded its degradation since
phosphorylated IjB was evident after 5 min and peaked
at 30 min, whereas degradation of IjB initiated after
30 min and was maximum at 120 min (31.2  19.6% of
the initial signal remaining) (Fig. 8B). These results are
consistent with NF-jB activation and suggest its
involvement in sPLA2-induced cytokine/chemokine
production. This hypothesis was explored by evaluating
the effect of two different inhibitors of NF-jB on
GIA-induced TNF-a and CXCL8 release. In these
experiments, HLM were preincubated (37C, 1 h) with
the proteasome inhibitor MG-132 (0.3–30 lM) that
prevents degradation of IjB [41], and with 6-amino-4-
phenoxyphenylethylamino-quinazoline
Figure 5.Activation of HLM by human GIB sPLA2. (A) Effect on cytokine and chemokine release: The cellswere preincubated (37
C,
1 h)withmediumalone, SB203580 (30 lM), PD98059 (50 lM) or both (30 lMSB203580 + 50 lMPD988059) and then stimulated (37C,
6 h) with the indicated concentrations of GIB. TNF-a and CXCL8 release was determined by ELISA. The data are the mean  SE of
four experiments. *p<0.05 vs. control; § p<0.05 vs. GIB. (B) Effect on p38 and ERK1/2 phosphorylation: hGIB (0.1–10 lg/mL) was
incubated (37C, 15 min)with orwithoutMe-indoxam (10 lg/mL) before being added toHLM (37C, 1 h).Western blot analysiswith
anti-phospho-p38 (first gel) and -phospho-ERK1/2 (third gel) Abwas performed. Strippedmembraneswere reblottedwith anti-p38
and -ERK2 Ab to confirm equal protein content of each sample. The Western blots shown are representative of three separate
experiments.
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(Quinazoline-11q: 0.1–10 lM) that blocks NF-jB tran-
scriptional activation [42], and were then stimulated
with GIA (10 lg/mL). The release of both TNF-a
(Fig. 8C) and CXCL8 (Fig. 8D) induced by GIA was
completely inhibited by the two compounds with IC50
values (MG-132: 1.80  0.48 lM for TNF-a and
1.71  0.29 lM for CXCL8; Quinazoline-11q:
0.40  0.10 lM for TNF-a and 0.63  0.16 lM for
CXCL8) consistent with those reported for inhibition
of NF-jB activity [41–43]. In the same experiments, the
two inhibitors completely blocked TNF-a and CXCL8
release induced by 1 lg/mL LPS, used as positive control
(data not shown). These results indicate that activation
of NF-jB is required for cytokine/chemokine production
induced by sPLA2 in HLM.
To gain further insight into the pathways leading to
the activation of NF-jB, we analyzed the effect of
ERK1/2, p38 and PI3 K inhibitors on sPLA2-induced
degradation of IjB. HLM were preincubated (37C, 1 h)
with optimal concentrations of PD98059 (50 lM),
SB203580 (30 lM), a combination of PD98059
(50 lM) + SB203580 (30 lM), LY294002 (30 lM) or
MG-132 (30 lM) and then stimulated with GIA for
120 min. At the end of the experiments, membranes
were incubated with anti-IjB (Fig. 9, upper gel) and,
after stripping, with anti-glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (Fig. 9, lower gel) to verify
equal protein loading. Degradation of IjB induced by
GIA was partially prevented by the PI3 K inhibitor
(LY294002), but it was not influenced by the inhibitor of
ERK1/2 (PD98059), p38 (SB203580) or their combina-
tion. As expected, MG-132 completely blocked GIA-
induced degradation of IjB. These results suggest that
PI3 K, but not ERK1/2 and p38 kinases, is involved in
sPLA2-induced activation of NF-jB.
Discussion
In this study we demonstrate that two distinct sPLA2
induce the production of a wide spectrum of cytokines
and chemokines from primary macrophages isolated
·
Figure 6. Effect of GIA sPLA2 on the activation of PI3 K/Akt
system in HLM. (A) Phosphorylation kinetics of p85a subunit of
PI3 K. The cells were stimulated with GIA (5 lg/mL) for the
times indicated. Reactions were stopped with the addition of
ice-cold PIPES buffer. The cells were microfuged and imme-
diately lysed. Precleared lysates were immunoprecipitated
with anti-p85a Ab and subjected to Western blot analysis with
anti-phospho-tyrosine Ab (first gel). Strippedmembraneswere
reblotted with anti-p85a Ab (second gel) to confirm equal
protein content of each sample. The Western blot shown is
representative of three separate experiments. (B, C) Phosphor-
ylation kinetics of Akt: (B) cells were stimulatedwith GIA (5 lg/
mL) for the times indicated. Protein extracts were subjected to
Western blot with two different Ab directed against Akt
phosphorylated at Thr308 (first gel) or Ser473 (second gel)
and, after stripping, with anti-unphosphorylated Akt Ab (third
gel) to confirm equal protein content of each sample. The
Western blot shown is representative of three separate
experiments. (C) Densitometric analysis of the phosphoryla-
tion kinetics of Akt was performed by measuring the signal
intensity at the various time points and by calculating the ratio
versus untreated samples (Ctr). Adequate normalization was
accomplished by measuring the signal intensity of unpho-
sphorylated form of Akt. The data are the mean  SE of the
three experiments.
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from human lung parenchyma. This spectrum comprises
both proinflammatory (TNF-a and IL-6) and immunor-
egulatory (IL-10) cytokines as well as chemokines of the
CC (CCL2, CCL3 and CCL4) and CXC (CXCL8) families.
The activating properties of sPLA2 are independent from
the enzymatic activity and require activation of signaling
events involving PI3 K, p38, ERK1/2 and NF-jB.
The profile of cytokines and chemokines induced in
HLM indicates that sPLA2 may have a major impact on
the initiation/modulation of lung inflammation and
immune responses. In particular, the release of large
amounts of TNF-a and IL-6 from sPLA2-activated HLM
indicates that sPLA2 may enhance the local inflamma-
tory responses, whereas the induction of CXCL8, CCL2,
CCL3 and CCL4 suggests that sPLA2 induce the
preferential recruitment of neutrophils and monocytes
at sites of inflammation. These in vitro observations may
help explain previous data obtained in vivo indicating
that administration of sPLA2 to the lung [44] and the
skin [45] is characterized by intense inflammatory
reactions and by influx of inflammatory cells, predo-
minantly neutrophils and monocytes. The physiological
relevance of our data is strengthened by the observation
that human GIB sPLA2 effectively activates HLM. This
isoform is highly expressed in the human lung [46] and
promotes severe inflammation when administered in
vivo [45].
Interestingly, sPLA2 display a certain degree of
selectivity. In fact, not all the cytokines and chemokines
produced by human macrophages are up-regulated by
sPLA2. For example, GIA has no influence on the
production of IL-12, CCL1 and CCL5 that are up-
regulated by LPS. Moreover, GIA did not induce the
release of CCL22, which is induced by IL-4. These
observations support the hypothesis that sPLA2 generate
a cascade of intracellular events that is highly regulated
in human macrophages.
Previous studies have shown that sPLA2 may activate
just one of the MAPK p38 or ERK1/2 in inflammatory
cells [5, 7, 9, 19]. For example, Baek et al. [9] have
shown that group IIA sPLA2 activates ERK1/2, but not
p38, in RAW264.7 macrophages. Two other studies in
neutrophils have shown that GIB may alternatively
activate p38 [5] or ERK1/2 [19]. Here we report that
p38 and ERK1/2 are activated simultaneously by sPLA2
in human macrophages and that they are both required
for optimal cytokine and chemokine production. In fact,
inhibition of either ERK1/2 (with PD98059) or p38
(with SB203580) resulted in the reduction of TNF-a and
CXCL8 release, whereas the simultaneous blockade of
the kinases completely suppressed cytokine/chemokine
secretion. These data indicate that p38 and ERK1/2
cooperate for optimal production of cytokines and
chemokines in sPLA2-activated human macrophages.
The enzymatic activity of sPLA2 is not required for
activation of p38 and ERK1/2 and for induction of
cytokine/chemokine production. These results are in
line with previous observations showing that catalyti-
cally inactive sPLA2 are still able to induce cytokine
production in human inflammatory cells [7, 16, 18].
However, we show that an intact secondary and tertiary
structure of sPLA2 is essential for macrophage activation
given that disruption of the disulfide bridges completely
abolishes the ability of GIA to induce MAPK activation
and cytokine/chemokine release. Our data also indicate
that Me-indoxam inhibits the activation of p38 and
ERK1/2 induced by GIB at concentrations (10 lM)
previously shown to block cytokine production in HLM
[18]. Me-indoxam prevents the binding of GIB with the
M-type receptor [34], which is expressed on HLM [18].
Figure 7. Role of PI3 K in GIA sPLA2-induced TNF-a/CXCL8
release and MAPK activation in HLM. (A) The cells were
preincubated (37C, 1 h) with LY294002 (3–30 lM) and then
stimulated (37C, 6 h) with GIA (10 lg/mL). TNF-a and CXCL8
releasewas determined in the supernatants by ELISA. The data
are the mean  SE of four experiments. *p<0.05 vs. sPLA2;
§ p<0.01 vs. sPLA2. (B) The cells were preincubated (37
C, 1 h)
with LY294002 (30 lM) and then stimulated (37C, 1 h) with GIA
(5 lg/mL).Western blot analysis with anti-phospho-p38 (first
gel) and -phospho-ERK1/2 (third gel) Ab was performed.
Stripped membranes were reblotted with anti-p38 (second
gel) and -ERK2 (fourth gel) Ab to confirm equal protein content
of each sample. TheWestern blots shown are representative of
three separate experiments.
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Thus, our results provide further evidence that sPLA2
activate human macrophages by interacting with the
M-type receptor or other membrane targets.
In mammalian cells, phosphorylation of MAPK is
determined by several intracellular cascades triggered
by membrane signals [47]. An early kinase mediating a
number of cellular responses in leukocytes is PI3 K [22,
24]. Studies inmurine systems reported the involvement
of PI3 K and Akt in the up-regulation of iNOS induced by
group IIA sPLA2 in RAW 264.7 macrophages [10], and in
the activation of matrix metalloproteinase-2 induced by
GIB sPLA2 in NIH3T3 fibroblasts [37]. Our data
demonstrate that, in primary human macrophages,
GIA activates the PI3 K/Akt pathway, which is required
for sPLA2-induced cytokine/chemokine production and
activation of ERK1/2. Moreover, the observation that
LY294002, an inhibitor of PI3 K, has no influence on p38
phosphorylation indicates that PI3 K is not involved in
the activation of this MAPK.
Figure 8. Role of NF-jB in GIA sPLA2-induced release of TNF-a and CXCL8 in HLM. (A, B) Kinetics of phosphorylation and
degradation of IjB. (A) The cells were stimulated with GIA (5 lg/mL) for the times indicated. Cellular protein extracts were
subjected to Western blot analysis with anti-phospho-IjBa Ab (first gel) and, after stripping, with anti-IjBa Ab (second gel). The
Western blot shown is representative of three separate experiments. (B) Densitometric analysis of the phosphorylation and
degradation kinetics of IjBwas performed bymeasuring the signal intensity at the various time points and by calculating the ratio
versus untreated samples (Ctr). Adequate normalization was accomplished by measuring the signal intensity of GAPDH used to
verify equal protein loading. The data are the mean  SE of the three experiments. (C, D) Effect of NF-jB inhibitors on sPLA2-
induced TNF-a and CXCL8 release. The cellswere preincubated (37C, 1 h) withMG-132 (0.3–30 lM) or Quinazoline-11q (0.1–10 lM)
and then stimulated (37C, 6 h) with GIA (10 lg/mL). TNF-a and CXCL8 release was determined in the supernatants by ELISA. The
data are the mean  SE of four experiments. *p<0.01 vs. GIA.
Figure 9. Role of p38, ERK1/2 and PI3 K in GIA sPLA2-induced
degradation of IjB. The cellswere preincubated (37C, 1 h) with
PD98059 (50 lM), SB203580 (30 lM), PD98059 (50 lM) plus
SB203580 (30 lM), LY294002 (30 lM) or MG-132 (30 lM) and
then stimulated (37C, 2 h) with GIA (5 lg/mL). Cellular protein
extractswere subjected toWestern blot analysiswith anti-IjBa
Ab (first gel) and, after stripping, with anti-GAPDH Ab (second
gel). The Western blots shown are representative of three
separate experiments.
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The production of cytokines and chemokines in-
duced by sPLA2 in HLM is associated with the activation
of gene transcription (Fig. 2), an event requiring the
activation of specific nuclear factors [20]. NF-jB is the
major nuclear factor regulating transcription of cyto-
kine/chemokine genes in macrophages [21, 48]. Our
results demonstrate that GIA induces the phosphoryla-
tion/degradation of IjB in HLM, and that two different
inhibitors of NF-jB suppress sPLA2-induced production
of TNF-a and CXCL8. These data support a crucial role of
NF-jB in sPLA2-induced activation of HLM. Data
obtained with inhibitors of the various kinases indicate
that only LY294002, an inhibitor of PI3 K, prevents the
signal to IjB, suggesting that PI3 K, but not p38 and
ERK1/2, is involved in the activation of the NF-jB
pathway by sPLA2. This hypothesis is strengthened by
the kinetics of phosphorylation of IjB, which is
comparable to that of PI3 K and Akt and precedes the
phosphorylation of p38 and ERK1/2. Current evidence
supports the concept that the PI3 K/Akt system may
participate in the pathways targeting NF-jB in immune
cells [24, 26, 38, 49], whereas p38 and ERK1/2 are
involved in cytokine/chemokine production through
NF-jB-independent pathways [48, 50]. However, the
full definition of the pathways leading to the activation
of NF-jB in human macrophages stimulated with sPLA2
requires further investigations.
Thus, multiple signaling cascades are activated by
sPLA2 in primary HLM and are involved in cytokine and
chemokine production. The interaction of sPLA2 with
membrane targets, that still need to be completely
characterized, activates at least three intracellular
pathways (Fig. 10). The first leads to the activation of
the early kinase PI3 K and the downstream Akt, which in
turn induces the activation of NF-jB presumably by
interacting with amember of the IjB kinase (IKK) family
[38, 49]. PI3 K also participates to the activation of
ERK1/2, which is not directly involved in the activation
of NF-jB, but activates other nuclear factors (e.g., Elk-1,
ATF-1/2, CREB) regulating cytokine/chemokine gene
transcription [20, 23]. This pathway likely involves the
members of the PKC family able to drive the signal of
PI3 K to Ras/Raf complexes and then to ERK1/2 [22–24,
47]. Finally, sPLA2 activate p38 by a signaling cascade
independent from the PI3 K/Akt system and leading to
the activation of nuclear factors other than NF-jB.
Further studies are necessary to characterize both the
early transducers located upstream to p38 and the
downstream nuclear factors targeted by this kinase.
In conclusion, this study identifies several intracel-
lular events mediating sPLA2-induced cytokine and
chemokine production in primary human macrophages.
These events may be potential targets for pharmacolo-
gical modulation of sPLA2-mediated responses in lung
inflammatory diseases.
Materials and methods
Reagents and buffers
The following were purchased: GIA sPLA2 (from Naja
mossambica mossambica venom), LPS (from E. Coli serotype
026:B6), fatty acid-free human serum albumin (HSA), BSA,
PIPES, L-glutamine, antibiotic-antimycotic solution
(10 000 UI/mL penicillin, 10 mg/mL streptomycin, and
25 lg/mL amphotericin B) and Triton X-100 (Sigma, St.
Louis, MO); BPB, DTT, RPMI 1640 and FCS (ICN, Costa Mesa,
CA); arachidonic acid (Biomol, Plymouth Meeting, PA); rabbit
Ab anti-phospho-ERK1/2 (Thr202/Tyr204), -phospho-p38
(Thr180/Tyr182), -phospho-Akt (Thr308), -phospho-Akt
(Ser473), -phospho-IjBa (Ser32), -Akt and -IjB and the
compounds PD98059 and LY294002 (Cell Signaling, Beverly,
MA); rabbit Ab anti-ERK2 (C-14) and -p38 (C-20), goat Ab
anti-GAPDH (V-18), horseradish peroxidase (HRP)-conjugated
goat anti-mouse IgG and rabbit anti-goat IgG (Santa Cruz
Biotechnology, Santa Cruz, CA); mouse anti-phosphotyrosine
Ab (4G10) and rabbit anti-p85a subunit of PI3 K Ab (Upstate,
Charlottesville, VI); HRP-conjugated donkey anti-rabbit Ig Ab
Figure 10. Schematic representation of the signaling pathways
involved in sPLA2-induced cytokine/chemokine production in
HLM. The interaction of sPLA2 with a membrane target
expressed on the macrophage membrane activates at least
three different signaling cascades involved in the production of
cytokines and chemokines. The activation of PI3 K is an early
event leading to the activation of two independent pathways
involving the MAPK ERK1/2 and the nuclear factor NF-jB. The
latter goes through Akt and, presumably, one of themember of
the IKK family, which phosphorylates IjB. On the other hand,
PI3 K-dependent activation of ERK1/2 likely involves the
members of the PKC family able to drive the signal of PI3 K
to Ras/Raf complexes, which in turn activate the MAPK
cascade. The third signaling pathway includes the activation
of p38 independently on PI3 K. Both the pathways involving
p38 and ERK1/2 directly or indirectly activate nuclear factors
other than NF-jB (e.g., Elk-1, ATF-1/2, CREB, etc.).
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(Amersham Biosciences, Buckinghamshire, UK); SB203580,
MG-132 (Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal;Z-LLL-
CHO) and 6-amino-4(4-phenoxyphenylethylamino) quinazo-
line (Quinazoline-11q) (Calbiochem, La Jolla, CA); IFN-c and
IL-4 (PeproTech, London, UK). Human recombinant GIB sPLA2
and Me-indoxam were kindly donated by Michael H. Gelb
(University of Washington, Seattle, WA). BPB- and DTT-
inactivated sPLA2 were prepared as previously described [6,
7]. All other reagents were from Carlo Erba (Milan, Italy).
PIPES buffer was made of 25 mM PIPES, 110 mM NaCl and
5 mM KCl. PCG buffer was made of PIPES buffer containing
1 mMCaCl2 and 1 g/L glucose, pH 7.4. Lysis buffer forWestern
blot experiments was made of 20 mM Tris pH 7.5, 5 mM
EDTA, 1 mM PMSF, 2 mM benzamidine, 30 lg/mL aprotinin,
30 lg/mL leupeptin, 10 mM NaF, 150 mM NaCl, 5 mM
Na3VO4, 1% Nonidet P-40 and 5% glycerol.
Isolation and purification of HLM
Macrophages were obtained from the lung parenchyma of
patients undergoing thoracic surgery as previously reported
[4]. The study protocol involving the use of human lung tissue
was approved from the Ethical Committee of the University of
Naples Federico II, and informed consent was obtained from
patients before surgery. The macrophage suspension was
enriched (75–85%) by flotation over PercollJ density gradi-
ents. The cells were suspended (106 cells/mL) in RPMI 1640
containing 5% FCS, 2 mM L-glutamine, and 1% antibiotic-
antimycotic solution and incubated in 24-well plates. After
12 h, the medium was removed and the plates were gently
washed with RPMI 1640. More than 98% of adherent cells
were macrophages, as assessed by flow cytometry analysis and
a-naphthylacetate esterase staining [18]. In the experiments
with freshly isolated macrophages, the enriched macrophage
suspension was layered onto additional Percoll gradients to
reach a purity ranging between 95% and 99%, as assessed by
CD71/HLA-DR double staining with flow cytometry [18].
Cell incubations
Adherent macrophages were incubated (37C, 2–24 h) in
RPMI 1640 containing increasing concentrations
(0.1–10 lg/mL) of GIA or GIB sPLA2. Commercial prepara-
tions of GIA were repurified by size exclusion chromatography
[7] before use. All sPLA2 preparations were routinely checked
for LPS contamination (Limulus Amebocyte Test, ICN) and
discarded if LPS concentration was above the detection limit of
the assay (0.125 EU/mL). In selected experiments, the cells
were preincubated (37C, 1 h) with or without IFN-c
(1000 U/mL) and then incubated (37C, 24 h) with optimal
concentrations of GIA (10 lg/mL) or LPS (1 lg/mL). In other
experiments, HLM were incubated (37C, 6 h) with GIA
(0.1–10 lg/mL) or LPS (1 lg/mL) either untreated or treated
with DMSO (vehicle), BPB (37C, 4 h) or DTT (37C, 2 h).
Control cells were incubated with DMSO, BPB or DTT in the
absence of sPLA2. Finally, in the experiments with the
inhibitors of intracellular kinases or NF-jB, HLM were
preincubated (37C, 1 h) with various concentrations of
PD98059, SB203580, LY294002, MG-132 or Quinazoline-11q
and then stimulated (37C, 6 h) with GIA or LPS. At the end of
each experiment, cell viability was assessed by trypan blue
exclusion and was always found to be greater than 95%.
At the end of incubation, supernatants were removed,
centrifuged twice (1000g, 4C, 5 min) and stored at –80C
for the subsequent determination of cytokines (TNF-a, IL-6,
IL-10, IL-12) and chemokines (CCL2, CCL4, CCL22 and
CXCL8). The cells remaining in the plates were lysed with
0.1% Triton X-100 for the determination of total cellular
content of proteins.
ELISA for cytokines and chemokines
The release of cytokines and chemokines in the supernatant of
macrophage cultures was measured in duplicate determina-
tions using commercially available ELISA kits for TNF-a, IL-6,
IL-10, IL-12 and CXCL8 (Euro Clone, Devon, UK) and CCL2,
CCL4 and CCL22 (R&D Systems, Minneapolis, MN). The
linearity range of the assay was between 20 and 800 pg/mL
(TNF-a), 6 and 200 pg/mL (IL-6 and IL-12), 12 and
400 pg/mL (IL-10), 15.6 and 1000 pg/mL (CCL2, CCL4), 7.8
and 500 pg/mL (CCL22), and 30 and 2000 pg/mL (CXCL8).
The results were normalized for the total protein content in
each well.
RPA for chemokine mRNA expression
Adherent macrophages (4  106/2 mL)were incubated (37C,
6 h) with RPMI 1640 alone, with increasing concentrations
(0.1–10 lg/mL) of GIA, or with LPS (10 lg/mL) that was used
as a positive control. At the end of incubation, RNA was
isolated by the TRIzol technique (Invitrogen,Milan, Italy). RPA
was performed as previously described [51]. Briefly, chemo-
kine mRNA were detected using the RiboQuant Multi-Probe
RPA kit (template set hCK-5; Pharmingen, San Diego, CA)
according the manufacturer's instructions. In brief, 32P-labeled
riboprobes were hybridized overnight with 5 lg RNA. The
hybridized RNAwas treatedwith RNase and purified according
to the RiboQuant protocol. Protected RNA were then resolved
on a 5% denaturing polyacrylamide gel. The gel was adsorbed
to filter paper, dried under vacuum, and exposed to film (X-AR;
Kodak, Rochester, NY) with intensifying screens at –70C.
Western blot analysis
Freshly isolated macrophages were suspended in PCG buffer.
The cells (106/sample) were incubated (37C, 1–120 min)
with the indicated concentrations of GIA or GIB sPLA2. In
selected experiments macrophages were preincubated (37C,
1 h) with PD98059, SB203580, LY294002 or MG-132 before
stimulation with sPLA2. At the end of incubation the reactions
were stopped by adding ice-cold PIPES buffer and the samples
were microfuged for 30 s. Cell pellets were immediately lysed
in lysis buffer. Cell lysates were kept on ice for 20 min and then
microfuged for 20 min at 4C. Supernatant was collected as a
protein extract containing lysed cell components without
nuclei and diluted in an equal volume of 2 LDS Sample Buffer
(LSB, Novex, Invitrogen, Milan, Italy) containing 2.5% 2-ME.
Proteins were separated on 10% Bis-Tris gels (NuPAGEJ,
Novex) and transferred to a nitrocellulose membrane (Bio-
Rad, Hercules, CA). After immersion overnight in TBST
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(50 mM Tris pH 7.5, 150 mM NaCl and 0.05% Tween 20)
containing 4% BSA, membranes were washed three times
(10 min each) with TBST, and then blotted (4C, overnight)
with the indicated Ab. After washing, the membranes were
incubated (22C, 1 h) with HRP-conjugated secondary Ab.
Membranes were washed four times and developed with the
ECLWestern blotting detection reagent (Amersham) under the
image analysis system ChemidocXRS (Bio-Rad). Although
comparisons were made on the basis of an equal number of
cells, membranes blotted with Ab against phospho-kinases
were stripped with stripping buffer (7 M guanidine hydro-
chloride in distilled water) and then reblotted with the Ab
against the unphosphorylated proteins to verify equal protein
content of each sample. Densitometric measurement of the
signal intensity was performed with the Quantity One 4.5.0
software (Bio-Rad) and kinase phosphorylation rate at the
various time points was obtained by calculating the ratio versus
untreated samples. Normalization was accomplished by
calculating the signal intensity of the unphosphorylated forms
of the various kinases or of GAPDH.
Immunoprecipitation of p85a subunit of PI3K
Freshly isolated macrophages suspended in PCG buffer
(5  106/sample) were incubated (37C, 1–15 min) with
GIA (5 lg/mL). At the end of incubation the reactions were
stopped by adding ice-cold PIPES buffer and the samples were
microfuged for 30 s. Cell pellets were immediately lysed in
1 mL lysis buffer. Cell lysates were kept on ice for 20 min and
then microfuged for 20 min at 4C. Lysates were precleared
with Gammabind G Sepharose beads (Amersham) for 1 h at
4C to remove any nonspecific binding. The clarified lysates
were then incubated (1 h, 4C) with the Ab against the p85a
subunit of PI3 K prebound to Gammabind G Sepharose beads
(1 h, 4C). Immunoprecipitated proteins were eluted by
boiling in LSB containing 2.5% 2-ME. Proteins were separated
on 4–12% Bis-Tris gels and transferred to a nitrocellulose
membrane. Immunoblotting with anti-phosphotyrosine Ab
(4G10) or, after stripping, with the anti-p85a subunit Ab was
performed as described above.
Statistical analysis
The data are expressed as the mean  SE of the indicated
number of experiments. p values were determined with
Student's paired t-test [52].
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